MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex
about
Concise review: Leukemia stem cells in personalized medicineAdvances in targeting signal transduction pathwaysNatural borneol, a monoterpenoid compound, potentiates selenocystine-induced apoptosis in human hepatocellular carcinoma cells by enhancement of cellular uptake and activation of ROS-mediated DNA damageCircumvention of Mcl-1-dependent drug resistance by simultaneous Chk1 and MEK1/2 inhibition in human multiple myeloma cellsThe Bcl-2/xL inhibitor ABT-263 increases the stability of Mcl-1 mRNA and protein in hepatocellular carcinoma cells.Rational combination of dual PI3K/mTOR blockade and Bcl-2/-xL inhibition in AML.Evaluation of apoptosis induction by concomitant inhibition of MEK, mTOR, and Bcl-2 in human acute myelogenous leukemia cells.Inhibiting CCN1 blocks AML cell growth by disrupting the MEK/ERK pathway.Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.Histone deacetylase inhibitors facilitate dihydroartemisinin-induced apoptosis in liver cancer in vitro and in vivo.New strategies in acute myelogenous leukemia: leukemogenesis and personalized medicine.Synergistic interaction between the HDAC inhibitor, MPT0E028, and sorafenib in liver cancer cells in vitro and in vivoCalcium signals inhibition sensitizes ovarian carcinoma cells to anti-Bcl-xL strategies through Mcl-1 down-regulation.Inhibition of IRAK1/4 sensitizes T cell acute lymphoblastic leukemia to chemotherapies.Rational Combinations of Targeted Agents in AMLInhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia.Cyclin E/Cdk2-dependent phosphorylation of Mcl-1 determines its stability and cellular sensitivity to BH3 mimeticsBCL-2 Antagonism to Target the Intrinsic Mitochondrial Pathway of Apoptosis.Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.Combination of galectin inhibitor GCS-100 and BH3 mimetics eliminates both p53 wild type and p53 null AML cells.Resistance to BH3 mimetic S1 in SCLC cells that up-regulate and phosphorylate Bcl-2 through ERK1/2.CXCR4 chemokine receptor signaling induces apoptosis in acute myeloid leukemia cells via regulation of the Bcl-2 family members Bcl-XL, Noxa, and BakMcl-1 as a Therapeutic Target in Acute Myelogenous Leukemia (AML).Depletion of γ-catenin by Histone Deacetylase Inhibition Confers Elimination of CML Stem Cells in Combination with ImatinibBCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells.Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia.Toward a cure for chronic lymphocytic leukemia: an attack on multiple frontsApoptosis repressor with caspase recruitment domain is regulated by MAPK/PI3K and confers drug resistance and survival advantage to AML.MLL-AF4 binds directly to a BCL-2 specific enhancer and modulates H3K27 acetylationComplementary dynamic BH3 profiles predict co-operativity between the multi-kinase inhibitor TG02 and the BH3 mimetic ABT-199 in acute myeloid leukaemia cellsBiomarkers of therapeutic response to BCL2 antagonists in cancer.That which does not kill me makes me stronger; combining ERK1/2 pathway inhibitors and BH3 mimetics to kill tumour cells and prevent acquired resistance.Advances towards the design and development of personalized non-small-cell lung cancer drug therapy.Targeting novel signaling pathways for resistant acute myeloid leukemia.Therapeutic targeting of Bcl-2 family for treatment of B-cell malignancies.Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1.Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myeloma.YM155 enhances ABT-737-mediated apoptosis through Mcl-1 downregulation in Mcl-1-overexpressed cancer cells.Synergistic cooperation between ABT-263 and MEK1/2 inhibitor: effect on apoptosis and proliferation of acute myeloid leukemia cells.MEK inhibitor effective against proliferation in breast cancer cell.
P2860
Q26995268-903A2B9F-AA58-45A9-A5AB-2F6479B63766Q27686983-C50DB0FA-33FA-418C-94E8-C1058D26FDA0Q28488280-9B0D2ABD-A460-435F-91CF-82835D0940C5Q28540339-4452CD57-12B4-42EF-A1FA-EA7FF81B95D5Q33612421-256518D6-DFB9-4B2C-8833-ECC0EF1F4FEFQ33840360-CF17C2F8-64F8-4F31-A482-BB19D9CF1B23Q33875609-B694B7A8-B124-4684-90C2-587F5D0D7BCFQ34127147-0D31D1F5-D4F4-4DDF-8656-CBD9A57C7B8DQ34307356-D0928C07-2A48-4AEE-A12D-E1C3B07EE708Q34326588-72D47F79-61FB-42B1-AA88-55B57B35399AQ34715598-541FB0EE-C554-465A-984D-1DB4D7239CFEQ34837850-50E6D7EE-3F08-4277-82E2-3789C0A7D738Q35143875-F980A442-FA3B-4BE4-B8DC-D2FC98D700CDQ35183900-DFF11E06-2DF5-4AC4-A790-90A4F4E3A290Q35750491-60E755EC-EA78-4DAE-BDD2-836D29FD4A2AQ35859229-9189FEEB-38FF-430A-91F4-86FAFDDBB8C4Q36231912-AA31C414-4EAB-4211-B4DC-E350FF568430Q36284637-E7CF4422-C0C8-48CC-87BE-9B894648825DQ36625664-F5C0AF4B-9833-4330-AB58-1886D9A82868Q36642752-9F35CE87-0333-46DC-BDF7-B50BAB85BB63Q37046792-88BD2292-E540-48C1-9CEA-11C9322C725BQ37095358-4EC5EDB1-5A04-4286-A2A2-1FFD56C2152CQ37104378-B9634603-3EDC-41CE-A786-0301596C3322Q37202328-CC7B4778-CD3D-4926-9230-72E120EEE692Q37235693-42DBC86B-F7E1-41A3-B865-19C9F2BAD78DQ37395704-77489CB4-81EE-4D2C-85CC-009A9E515D27Q37542942-96BC9079-30F4-450E-9592-75295E834FABQ37619463-75C11D87-C843-4E3F-AF3F-3FC94704E7F2Q37676956-C119EDDA-BF3B-4722-800E-A12DB93BDC71Q37725409-68ED5664-3FAF-4F9F-84D9-40400C807400Q38047846-A99F0A97-456A-41F6-A88B-00F6AEFC3866Q38104439-04641AEC-17C6-46A9-B95C-3DBA87AAC319Q38148583-4ADEA6C8-7FC0-424A-B66C-DDD2550E4255Q38297507-22421BB4-F14E-4F3F-9655-EA249A8ACB12Q38442515-868FC0EB-2171-493C-AF62-C24FD6C37D25Q38650669-F7B9C8AA-78D6-4747-805E-BCE0A0CFFFE0Q38718393-1ACA0856-21EB-418E-BEF3-0E386EDDF6B4Q38719564-CD51A3D9-9B28-4A46-B89A-800FC9710825Q38815323-4A172E61-0304-4938-ADD2-99888F6D40D5Q38983737-D1923ECD-15BF-40B6-AD76-07823F046787
P2860
MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
MEK inhibition enhances ABT-73 ...... odulation of MCL-1/BIM complex
@ast
MEK inhibition enhances ABT-73 ...... odulation of MCL-1/BIM complex
@en
type
label
MEK inhibition enhances ABT-73 ...... odulation of MCL-1/BIM complex
@ast
MEK inhibition enhances ABT-73 ...... odulation of MCL-1/BIM complex
@en
prefLabel
MEK inhibition enhances ABT-73 ...... odulation of MCL-1/BIM complex
@ast
MEK inhibition enhances ABT-73 ...... odulation of MCL-1/BIM complex
@en
P2093
P2860
P356
P1433
P1476
MEK inhibition enhances ABT-73 ...... odulation of MCL-1/BIM complex
@en
P2093
J McCubrey
M Andreeff
M Konopleva
M R Ricciardi
P2860
P2888
P304
P356
10.1038/LEU.2011.287
P577
2011-11-08T00:00:00Z
P5875
P6179
1046838173